

Role of catalytic function in the antiplatelet activity of phospholipase A₂ cobra (*Naja naja naja*) venom

L.M.S. Rudrammaji,¹ K. Deepa Machiah,¹ T.P. Krishna Kantha² and T. Veerabasappa Gowda

¹Department of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysore; ²Department of Biochemistry and Nutrition, Central Food Technology Research Institute, Mysore, India

Received 3 May 2000; accepted 18 December 2000

Abstract

Three acidic phospholipases A₂ from Indian cobra (*Naja naja naja*) venom inhibited platelet aggregation in platelet rich plasma induced separately by ADP, collagen and epinephrine with different potencies. The order of inhibition was epinephrine > collagen > ADP. They did not inhibit platelet aggregation induced by arachidonic acid (10 μM). The inhibition was dependent on concentration of the protein and the time of incubation of the phospholipases A₂ with platelet rich plasma. Parabromophenacyl bromide modified PLA₂ enzymes lost their enzymatic activity as well as platelet aggregation inhibition activity suggesting the involvement of catalytic function in platelet aggregation inhibitory activity. (Mol Cell Biochem **219**: 39–44, 2001)

Key words: platelet aggregation inhibitors, acidic phospholipases, antiplatelet activity, catalytic function, phospholipases A₂

Introduction

Snake venom phospholipases A₂ (PLA₂) are known to exhibit a broad spectrum of pharmacological activities such as neurotoxicity, cardiotoxicity, cytotoxicity, effects on platelet aggregation, hemolytic, pro- and anticoagulant, edema inducing and hypotensive [1, 2]. Phospholipases A₂ exhibiting these activities, in synergism with other venom protein may help in the acquisition and/digestion of the prey under natural conditions. The venom PLA₂ provides useful tools for understanding molecular events in normal physiology as well as new targets of drug development for clinical use.

Platelet aggregation is an important cellular process in thrombosis and hemostasis [3]. Several snake venom PLA₂ potentiates initiation and/inhibition of platelet aggregation. Acidic phospholipases are also among the PLA₂, which interfere in platelet functions. The role of catalytic activity of the PLA₂ enzyme in the inhibition of agonist induced platelet aggregation has been addressed by several groups [2, 4–11]. The results are varying from enzyme to enzyme suggesting that the individual PLA₂ effect inhibition of platelet aggregation differently. Present paper deals with role of catalytic activity of phospholipases A₂ from *Naja naja naja*

venom on platelet aggregation induced by agonists such as epinephrine, collagen, adenosine diphosphate (ADP) and arachidonic acid.

Materials and methods

Arachidonic acid, ADP, collagen and epinephrine were purchased from Sigma Chemical Co. St. Louis, USA. 1-nitroso-2-naphthol was purchased from Sigma Chemical Co. St. Louis, USA. Phosphatidyl choline (PC) was prepared from hen's egg yolk according to the method of Singleton *et al.* [12]. Human blood samples were from healthy volunteers from Department of studies in Biochemistry, Manasagangotri, Mysore, India and Central Food Research Institute (CFTRI) Mysore, India. All other chemicals used were of analytical grade.

Purification of the acidic phospholipases A₂ from Naja naja naja venom

The three acidic PLA₂ (NN-I_{2c}, NN-I_{2d} and NN-I_{2e}) were purified from *Naja naja naja* venom as described in our previ-

ous paper [13]. Indian cobra venom was fractionated on a CM-Sephadex C-25 column according to the method of Bhat and Gowda [14]. This resolved the venom into 14 peaks. The non-retained protein was eluted, as peak I (NN-I-PLA₂). NN-I-PLA₂ was resolved into three peaks upon gel filtration through a Sephadex G-50 column. The peaks were named as NN-I₁, NN-I₂ and NN-I₃. The enzyme elution profile showed the presence of PLA₂ activity in NN-I₂ (NN-I₂-PLA₂). NN-I₂-PLA₂ gave several coomassie blue stained bands on native-PAGE. This fraction was resolved into five peaks on a QAE-Sephadex A-25 column chromatography. They were named NN-I_{2a}-PLA₂, NN-I_{2b}-PLA₂, NN-I_{2c}-PLA₂, NN-I_{2d}-PLA₂ and NN-I_{2e}-PLA₂ [13]. In the present study, NN-I_{2c}, NN-I_{2d} and NN-I_{2e}, PLA₂ were used to investigate their effect on platelet aggregation.

Phospholipase A₂ assay

Phospholipase A₂ activity was assayed by estimating the free fatty acid released as described by Bhat and Gowda [14], using egg phosphatidyl choline as substrate. The incubation mixture contained 1 μM of egg phosphatidyl choline, 0.2 ml of diethyl ether, 0.05 M Tris-HCl buffer (pH 7.5) 40 mM Ca²⁺ and 0.2 ml of enzyme (2–5 μg) in 1 ml. The free fatty acid released was extracted as cobalt soap and was complexed with 1-nitroso 2-naphthol and estimated colorimetrically. Activity is expressed as nmoles of free fatty acid released/min/mg of protein.

Isolation of platelets

Human blood was collected from the vein of healthy non-smoker volunteers who had not taken any medication for at least the previous 2 weeks. Nine volumes of blood was collected into one volume of acid citrate dextrose (93 mM Sodium citrate, 7 mM citric acid and 140 mM glucose, pH 6.5) and immediately centrifuged for 10 min at 90 × g at room temperature (25°C). The supernatant obtained was collected as platelet rich plasma (PRP). Homologous platelet poor plasma (PPP) was prepared by recentrifugation of the remaining blood for 15 min at 500 × g at 25°C. The platelet concentration of PRP was adjusted with PPP to 2,25,000 ± 25,000 platelets/μl. The PRP was kept at 37°C and was used within 3 h after preparation. All the above preparation was carried out using plasticware or siliconized glassware.

Platelet aggregation

Platelet aggregation was studied by the turbidometric method of Born [15], using a chronolog dual channel aggregometer connected to omniscrite dual pen recorder to record the light

transmission as a function of time. Briefly, the action of agonist on platelets is measured by increased light transmission. When a platelet aggregating agent (agonist) is added to PRP, the platelet clump and PRP becomes progressively clear, showing increased light transmission with time. For concentration dependent platelet aggregation studies, different concentrations (0–24 μg/ml) of NN-I_{2c}-PLA₂, NN-I_{2d}-PLA₂ and NN-I_{2e}-PLA₂ were preincubated separately with PRP with constant stirring for 2 min. For time dependent platelet aggregation studies, aliquots of PRP were preincubated with each of the above mentioned enzymes (10 μg/ml) for different time intervals (2–60 min). Platelet aggregation of treated PRP was then initiated by addition of ADP (76 μM), collagen (~ 2 μg/ml), epinephrine (22 μM), and arachidonic acid (10 μM) separately. Percent inhibition was calculated assuming the values of control (without any aggregation inhibitor) to be 100%.

Chemical modification of phospholipases A₂ by p-bromophenacyl bromide

Chemical modification of PLA₂ by p-bromophenacyl bromide (p-BPB) was carried out as described by Condrea *et al.* [16]. One hundred microliters of 40 mM p-BPB in acetone were added to 3 ml of PLA₂ solution (0.5 mg/ml, in 0.05 M Tris-HCl buffer, pH 7.5). The reaction was allowed to proceed for 40 min, and then acidified with glacial acetic acid to pH 4.0 to stop the reaction. Excess of reagent was removed by dialysing against 0.05 M Tris-HCl buffer pH 7.5.

Determination of protein

Protein was estimated according to the method of Lowry *et al.* [17], using Bovine serum albumin as standard (0–75 μg).

Results

The three PLA₂ isoforms from *Naja naja naja* venom NN-I_{2c}, NN-I_{2d}, and NN-I_{2e} were purified to homogeneity using combinations of ion exchange and gel filtration chromatographies [13]. The PLA₂'s showed high catalytic activity. The specific activity, K_m and V_{max} of the three PLA₂ isoforms are given in Table 1.

The effect of these PLA₂ isoforms in platelet aggregation was determined using PRP sample. All three PLA₂ isoforms inhibits platelet aggregation induced by each of the agonist epinephrine, collagen and ADP. Figure 1 represents a typical inhibition pattern of platelet aggregation induced by all three agonist with NN-I_{2c}-PLA₂. The inhibition is dose dependent for all the three agonist induced platelet aggregation; with ADP and collagen induced platelet aggregation, maximum inhibition was observed at 24 μg/ml, whereas with

Table 1. Comparative phospholipase_A₂ activity of NN-I_{2c}-PLA₂, NN-I_{2d}-PLA₂, NN-I_{2e}-PLA₂

	Specific activity*	K _m (μM)	V _{max} (μM)
NN-I _{2c} -PLA ₂	9.0 ± 0.3	0.32	0.49
NN-I _{2d} -PLA ₂	13.0 ± 0.5	0.42	0.74
NN-I _{2e} -PLA ₂	16 ± 0.5	0.38	0.94

*Specific activity is expressed in terms of μM of fatty acid released/min/mg of protein. Data are mean values ± S.E.M. obtained with 6 experiments.

epinephrine induced platelet aggregation, maximum inhibition was observed even at 9 μg/ml. Similar pattern of dose dependent inhibition was observed for the other two PLA₂ isoforms. These PLA₂ isoforms inhibited platelet aggregation induced by epinephrine at low protein concentration on the other hand they required high protein concentration to inhibit platelet aggregation induced by ADP and collagen. Interest-

ingly these three PLA₂ isoforms failed to inhibit platelet aggregation induced by arachidonic acid.

The inhibition of agonists induced platelet aggregation by inhibitors depends on the duration of preincubation time of platelets with inhibitors before inducing aggregation with agonist. Figure 2 shows the effect of preincubation time with platelets at low concentration of all PLA₂ isoforms. Preincubation effect was observed with ADP induced platelet aggregation. The inhibition of platelet aggregation increased with preincubation time. Among all three isoforms, NN-I_{2e} showed higher inhibition. Time dependent aggregation studies are not presented for the other two agonist as similar patterns were observed.

All three PLA₂ isoforms inhibits platelet aggregation in a dose dependent manner induced by ADP (Fig. 3A), collagen (Fig. 3B) and epinephrine (Fig. 3C). Maximum inhibition of 20–30% was observed at 24 μg/ml of PLA₂ isoforms with ADP induced platelet aggregation (Fig. 3A), whereas collagen induced platelet aggregation was inhibited to 70–100% at the same concentration. Much stronger inhibition of 60–100% was observed with 9 μg/ml of PLA₂ isoforms with epinephrine induced platelet aggregation. NN-I_{2d} PLA₂ inhibited platelet aggregation induced by ADP to a greater extent. NN-I_{2e} PLA₂ inhibited platelet aggregation induced by collagen and epinephrine to a greater extent than NN-I_{2c} and NN-I_{2d} PLA₂.

All PLA₂ isoforms exhibit/showed similar affinity for phospholipid and its hydrolysing activity. The specific activity was ranging from 9–16 μM of fatty acid released/min/mg of protein. The maximum concentration of protein used in ADP and collagen induced platelet aggregation inhibition studies was 24 μg and less in epinephrine induced platelet aggregation. At these protein concentrations the amount of




Fig. 1. Inhibition of ADP (A), collagen (B) and epinephrine (C) induced platelet aggregation by NN-I_{2c}-PLA₂. PRP was incubated with NN-I_{2c}-PLA₂ (0–24 μg/ml) for 2 min at 37°C. Inhibition of platelet aggregation initiated by the addition of ADP (76 μM), collagen (~ 2 μg/ml), epinephrine (22 μM) was recorded.




Fig. 2. Inhibition of platelet aggregation by phospholipase A₂ NN-I_{2c} (●) NN-I_{2d} (○) AND NN-I_{2e} (▼) with time. Each PLA₂ (10 μg/ml) was preincubated with PRP for different time intervals at 37°C. Platelet aggregation was initiated by the addition of ADP (76 μM). Each value represents mean ± S.E.M. of 6 experiments.




Fig. 3. Effect of phospholipase A₂ NN-I_{2c} (●), NN-I_{2d} (○) AND NN-I_{2e} (▼) concentration on (A) ADP (B) collagen (C) epinephrine induced platelet aggregation. Different concentrations of PLA₂ were separately incubated with PRP for 2 min at 37°C. The platelet aggregation initiated by addition of ADP (76 µM), Collagen (~ 2 µg/ml), epinephrine (22 µM) separately was recorded. Each value represents mean ± S.E.M. of 6 experiments.

fatty acid released was less than 1 µM when phosphatidyl choline was used as the substrate. An equivalent amount of lysophospholipid was also expected to be released.

We examined the role of catalytic activity in the agonists induced platelet aggregation. p-BPB inhibits PLA₂ activity by modifying Histidine-48 residue which is essential for the catalytic function of PLA₂ [18]. In the present investigation modification of all the PLA₂ isoforms by p-BPB resulted in the complete loss of enzyme activity (Table 2). The chemically modified PLA₂ isoforms failed to inhibit platelet aggregation induced by the three agonist. Figure 4 represents the effect of modified NN-I_{2c} PLA₂ on the inhibition of platelet aggregation induced by ADP, collagen and epinephrine.

Discussion

Platelet aggregation is induced by large number of physiological agents such as ADP, serotonin, epinephrine, collagen, thrombin and A23187 ionophore [18]. The platelets interact through a specific receptor mechanism, which mediates shape change, aggregation and release reaction. In the present in-




Fig. 4.

Table 2. PLA₂ activity of native and p-BPB modified PLA₂ isoenzymes

Isoenzymes	Specific activity*	
	Native	p-BPB modified
NN-I _{2c} -PLA ₂	8.7 ± 0.4	0.1 ± 0.06
NN-I _{2d} -PLA ₂	12.8 ± 0.6	0.3 ± 0.05
NN-I _{2e} -PLA ₂	16.5 ± 0.3	0.5 ± 0.1

*Specific activity is expressed in terms of µM of fatty acid released/min/mg of protein. Data are mean values ± S.E.M. obtained with 6 experiments.

investigation the effect of PLA₂ isoforms on platelet aggregation induced by agonist such as ADP, collagen, epinephrine and arachidonic acid was carried out. Platelet aggregation in response to ADP and epinephrine release serotonin and nucleotides mostly ADP, which further initiates aggregation [19–21]. When collagen is the stimulating agent, aggregation is caused by adhesion to platelets followed by release of platelet serotonin and ADP [22–23]. Arachidonic acid induced platelet aggregation is due to the inhibition of thromboxane synthase by its metabolites of the lipoxygenase pathway [24], or due to interference with agonist receptor interaction [25].

Snake venoms are a source of toxins which interfere/modify the process of hemostasis. [3, 26]. The phospholipases of the venoms are one of the major components associated with this function. Based on their effects on the platelet function, venom PLA₂ enzymes can be divided into three major classes: (a) initiate platelet aggregation [8, 11], (b) inhibit platelet aggregation [6, 26–28] and (c) exhibit biphasic effects (initiate aggregation at low concentration or with short incubation time but inhibit aggregation at high concentration or with long incubation time) [11, 29].

The three acidic PLA₂'s purified from Indian cobra *Naja naja naja* venom, are catalytically highly active when compared to the basic PLA₂'s. So far no pharmacological property associated with the acidic PLA₂ have been reported. All the three isoforms of PLA₂ (NN-I_{2c}, NN-I_{2d}, and NN-I_{2e}) did not induce aggregation of platelets but actively inhibited the platelet aggregation induced by the agonists epinephrine, collagen and ADP. The inhibition of platelet aggregation by PLA₂ isoforms is concentration dependent. Hence these PLA₂ isoforms do not belong to either group (a) or (c) therefore they may be placed under group (b).

An acidic PLA₂ from *Akistrodon acutus* venom initiates aggregation by enzymatic hydrolysis of platelet phospholipids and inhibits platelet aggregation in PRP which was not dependent on protein concentration [4]. Platelet aggregation inhibition exhibited by *Akistrodon halys* PLA₂ is independent of PLA₂ activity [2]. However, the inhibition exhibited by the three isoforms of PLA₂ isolated from *Naja naja naja* venom is dependent on concentration and the PLA₂ activity of the enzyme.

The PLA₂ may cause a limited hydrolysis of membrane phospholipids and release arachidonic acid [30–31]. The arachidonate is an agonist, which can induce platelet aggregation/enhance the aggregation induced by the agonist mentioned above [32]. In contrast, arachidonate and lysophosphatidylcholine can also, serve as antagonist of platelet aggregation induced by collagen [31]. The lysophosphatidylcholine formed by the digestion of phospholipids by the PLA₂ enzymes also have effects on the platelet [33]. Therefore the PLA₂ should have served as agonist of platelet aggregation as their action results in the formation of arachidonate and lysophosphotides [32]. However all the isoforms of PLA₂ investigated in this

study inhibited the platelet aggregation induced by the agonists epinephrine, collagen and ADP.

The pattern of inhibition brought about by PLA₂ isoforms appears to differ depending on the agonists responsible for platelet aggregation. When identical concentrations of PLA₂ isoforms are used against the platelet aggregation induced by ADP and collagen, a dose dependent platelet aggregation inhibition was observed (Figs 3A and 3B). The extent of inhibition was not comparable especially at higher concentrations of the isoforms of PLA₂. The present study indicates the result of PLA₂ action on platelets which may not be due to release of agonists such as arachidonate and lysophosphotides, but due to modification brought about on the surface of the platelets. The inhibition could be due to the reduced pseudopod induction in the presence of the inhibitor [34].

The platelet aggregation induced by the third agonist in this study, epinephrine is also inhibited by the PLA₂ isoforms from *Naja naja naja* venom. The amount of PLA₂ isoforms present to inhibit platelet aggregation is much lower when compared to the other two agonists used ADP and collagen (Figs 3A–3C). Therefore the amount of arachidonate and lysophosphatides that may be released by these PLA₂ isoforms from the platelets should be lower and should enhance platelet aggregation. Since arachidonate can bring about the platelet aggregation at a concentration range of 0.1–2 μM [32], the PLA₂ concentration used in the study are expected to release arachidonate in this range. It can be seen from the platelet aggregation inhibition by the PLA₂ isoforms when ADP (Fig. 3A) is the agonist, it is about 10% at a PLA₂ concentration of 12 μg. On the other hand the same inhibitory effect is observed at half the concentration of the PLA₂ when epinephrine (Fig. 3C) is used as the agonist. But the extent of inhibition of aggregation observed was markedly higher when compared to the inhibition of platelet aggregation induced by collagen and ADP. This indicates that the platelet aggregation inhibited by the PLA₂ isoforms is not due to the release of arachidonate and lysophosphotides but due to specific modification of the platelets by the catalytic activity of the PLA₂ isoforms. Further, if the fluidity of the membrane is decreased it can lead to reduced interaction among the platelets [35, 36].

Chemical modification of the PLA₂ by p-BPB results in the modification of histidine-48 of the PLA₂ enzymes. Such a modification has been demonstrated to abolish the PLA₂ activity of the enzyme [16, 37]. In our study the chemical modification of all the three isoforms of PLA₂ by p-BPB resulted in the loss of catalytic activity. The chemically modified PLA₂ isoforms lost their platelet aggregation activity induced by epinephrine, collagen and ADP. This further strengthens the involvement of catalytic function in platelet aggregation process. The evidences present in this paper clearly indicate that (a) PLA₂ alters the platelets by their catalytic function, (b) this modification is differentially rec-

ognized in the aggregation process induced by the different agonists.

Acknowledgements

We thank Dr. B.S. Vishwanath, Reader, DOS In Biochemistry, University of Mysore for his valuable suggestions in the discussion of the paper. L.M.S.R. acknowledges the financial assistance from University Grants Commission, New Delhi, India.

References

- Kini RM, Evans HJ: A model to explain the pharmacological effects of snake venom phospholipases A_2 . *Toxicon* 27: 613–635, 1989
- Huang HC, Yeh HI, Ouyang C: Mechanism of the platelet aggregation inhibitor purified from *Agkistrodon halys* (mamushi) snake venom. *Toxicon* 22: 243–251, 1984
- Kini RM, Evans HJ: Effects of snake venom proteins on blood platelets. *Toxicon* 28: 1387–1421, 1990
- Chen RH, Chen YC: Isolation of an acidic phospholipase A_2 from the venom of *Agkistrodon acutus* (Five pace snake) and its effect on platelet aggregation. *Toxicon* 27: 675–682, 1989
- Kini RM, Evans HJ: Correlation between the enzymatic activity, anticoagulant and antiplatelet effects of phospholipase A_2 isoenzyme from *Naja nigricollis* venom. *Thromb Haemostat* 60: 170–173, 1988
- Li YS, Liu KF, Wang QC, Ran YL, Tu GC: A platelet function inhibitor purified from *Vipera russelli siamensis* (Smith) snake venom. *Toxicon* 23: 895–903, 1985
- Ouyang C, Huang TF: Effect of the purified phospholipases A_2 from snake and bee venoms on rabbit platelet function. *Toxicon* 22: 705–718, 1984
- Ouyang C, Teng CM, Chen YC: Properties of fibrinogen degradation products produced by α and β -fibrinogenases of *Trimeresurus mucrosquamatus* snake venom. *Toxicon* 17: 121–126, 1979
- Prasad BN, Kemparaju K, Bhatt KGS, Gowda TV: A platelet aggregation inhibitor phospholipase A_2 from Russell's viper (*Vipera russelli*) venom: Isolation and characterization. *Toxicon* 34: 1173–1185, 1996
- Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y: Venom from southern copperhead snake (*Agkistrodon contortrix contortrix*) II. A unique phospholipase A_2 that induces platelet aggregation. *Toxicon* 26: 199–206, 1988
- Teng CM, Kuo YP, Lee LG, Ouyang C: Effect of cobra venom phospholipase A_2 on platelet aggregation in comparison with those produced by arachidonic acid and lysophosphatidylcholine. *Thromb Res* 44: 875–886, 1986
- Singleton WS, Gray MS, Brown ML, White JL: Chromatographically homogenous lecithin from egg phospholipids. *J Am Oil Chem Soc* 42: 53–56, 1965
- Rudrammaji LMS, Gowda TV: Purification and characterization of three Acidic, cytotoxic phospholipases A_2 from Indian Cobra (*Naja naja naja*) venom. *Toxicon* 36: 921–932, 1998
- Bhat M, Gowda TV: Purification and characterization of myotoxic phospholipase A_2 from Indian cobra (*Naja naja naja*) venom. *Toxicon* 27: 861–874, 1989
- Born GVR: Quantitative investigation into the aggregation of blood platelets. *J Physiol* 162: 67–72, 1962
- Condrea E, Fletcher JE, Rapuano BE, Yang CC, Rosenberg P: Effect of modification of one histidine residue on the enzymatic and pharmacological properties of a toxic phospholipase A_2 from *Naja nigricollis* snake venom and less toxic phospholipases A_2 from *Haemachatus haemachatus* and *Naja naja atra* snake venoms. *Toxicon* 19: 61–71, 1981
- Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the folin-phenol reagent. *J Biol Chem* 193: 265–275, 1951
- Zucker MB: Platelet aggregation measured by photometric method. *Meth Enzymol* 169: 117–133, 1989
- Mills PCB, Robb IA, Roberts GCK: The release of nucleotides, 5-hydroxy tryptamine and enzymes from human platelets during aggregation. *J Physiol* 195: 715–729, 1968
- O'Brien JRA: Comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. *J Clin Path* 17: 275–281, 1964
- Salzman EW, Chamberr DA, Neri LL: Possible mechanism of aggregation of blood platelets by adenosine diphosphate. *Nature* 210: 167–169, 1966
- Hovig T: Aggregation of rabbit blood platelets produced *in vitro* by saline 'extracts' of tendons. *Thromb Diather Maemorh* 9: 248–263, 1963
- Spaet TH, Zucker MB: Mechanism of platelet plug formation and role of adenosine diphosphate. *Am J Physiol* 206: 1267–1274, 1964
- Hamberg M, Svensskon J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. *Proc Natl Acad Sci USA* 72: 2994, 1981
- Fratantoni JC, Poindexter BJ: Characterization of the platelet response to exogenous arachidonic acid. *Thromb Res* 22: 157–166, 1981
- Li YS, Liu KF, Wang QC: Mechanism of action of the platelet function inhibitor purified from *Vipera russelli siamensis* snake venom. *Toxicon* 24: 875–883, 1986
- Laing GD, Kamiguti AS, Wilkinson MC, Lowe GM, Theakston RDG: Characterization of a purified phospholipase A_2 from the venom of the Papuan black snake (*Pseudechis papuanus*). *Biochim Biophys Acta* 1250: 237–143, 1995
- Kemparaju K, Krishnakanth TP, Veerabasappa gowda T: Purification and characterization of a platelet aggregation inhibitor acidic phospholipase A_2 from Indian saw-scaled viper (*Echis carinatus*) venom. *Toxicon* 35: 1659–1671, 1999
- Kini RM, Evans HJ: Effect of phospholipase A_2 enzymes on platelet aggregation. In: *Venom Phospholipase A_2 Enzymes. Structure, Function and Mechanism*. John Wiley and Sons, 1997, pp 369–387
- Kanagi R, Koizumi K, Masuda T: Limited hydrolysis of platelet membrane phospholipids on the proposed phospholipase susceptible domain in platelet membrane. *J Biol Chem* 256: 1177–1182, 1981
- Teng CM, Chen YH, Ouyang C: Biphasic effect on platelet aggregation by phospholipase A_2 purified from *Vipera russelli* snake venom. *Biochim Biophys Acta* 772: 393–402, 1984
- Silver MJ, Smith JB, Ingerman C, Kocsis JJ: Arachidonic acid induced platelet aggregation and prostaglandin formation. *Prostaglandins* 4: 863–866, 1973
- Joist JH, Dolezel G, Cucuianu MP, Wishizawe EE, Mustard JF: Inhibition and potentiation of platelet function by lysolecithin. *Blood* 49: 101, 1977
- Feiye MAH, Heemskerk JWM, Hornistra G: Membrane fluidity of activated and nonactivated human blood platelets. *Biochim Biophys Acta* 1025: 1173–1178, 1990
- Shatil SJ, Anaya-Galimbodo R, Bennett J, Colman RW, Cooper RA: Platelet hypersensitivity induced by cholesterol incorporation. *J Clin Invest* 55: 636–643, 1975
- Shatil SJ, Cooper RA: Membrane micro viscosity and human platelet function. *Biochemistry* 15: 4832–4837, 1976
- Fuly AL, Machado OLT, Alves EW, Carlini CR: Mechanism of inhibitory action on platelet activation of a phospholipase A_2 isolated from *Lacheis muta* (Bushmaster) snake venom. *Thromb Haemostat* 78: 1372–1380, 1997